{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:50:14Z","timestamp":1790621414003,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00732-y","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T03:52:50Z","timestamp":1746071570000},"page":"1039-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patient Experience of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Qualitative Exploration of Signs, Symptoms, and Health-Related Quality of Life Impacts"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8224-6308","authenticated-orcid":false,"given":"Anna","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Thiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson L.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Minor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Hawken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"3\u20134","key":"732_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000494291","volume":"52","author":"MC Broers","year":"2019","unstructured":"Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 2019;52(3\u20134):161\u201372. https:\/\/doi.org\/10.1159\/000494291.","journal-title":"Neuroepidemiology"},{"issue":"4","key":"732_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/s1474-4422(10)70041-7","volume":"9","author":"JM Vallat","year":"2010","unstructured":"Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 2010;9(4):402\u201312. https:\/\/doi.org\/10.1016\/s1474-4422(10)70041-7.","journal-title":"Lancet Neurol"},{"issue":"6","key":"732_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/1756285612457215","volume":"5","author":"KC Gorson","year":"2012","unstructured":"Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord. 2012;5(6):359\u201373. https:\/\/doi.org\/10.1177\/1756285612457215.","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"732_CR4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","volume":"86","author":"KM Emily","year":"2015","unstructured":"Emily KM, Susanna BP, Richard ACH, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86(9):973. https:\/\/doi.org\/10.1136\/jnnp-2014-309697.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"732_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force\u2014second revision. J Peripher Nerv Syst. 2021;26(3):242\u201368. https:\/\/doi.org\/10.1111\/jns.12455.","journal-title":"J Peripher Nerv Syst"},{"issue":"7","key":"732_CR6","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1111\/ene.15341","volume":"29","author":"H Mork","year":"2022","unstructured":"Mork H, Motte J, Fisse AL, et al. Prevalence and determinants of pain in chronic inflammatory demyelinating polyneuropathy: results from the German INHIBIT registry. Eur J Neurol. 2022;29(7):2109\u201320. https:\/\/doi.org\/10.1111\/ene.15341.","journal-title":"Eur J Neurol"},{"key":"732_CR7","unstructured":"Gogia B, Rocha Cabrero F, Khan Suheb M, Rai R. Chronic inflammatory demyelinating polyradiculoneuropathy. Treasure Island: StatPearls Publishing; 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563249\/."},{"issue":"9","key":"732_CR8","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s00415-017-8578-9","volume":"264","author":"E Spina","year":"2017","unstructured":"Spina E, Topa A, Iodice R, Tozza S, Ruggiero L, Dubbioso R, et al. Early predictive factors of disability in CIDP. J Neurol. 2017;264(9):1939\u201344. https:\/\/doi.org\/10.1007\/s00415-017-8578-9.","journal-title":"J Neurol"},{"key":"732_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.638816","volume":"12","author":"SR Beydoun","year":"2021","unstructured":"Beydoun SR, Sharma KR, Bassam BA, Pulley MT, Shije JZ, Kafal A. Individualizing therapy in CIDP: a mini-review comparing the pharmacokinetics of Ig with SCIg and IVIg. Front Neurol. 2021;12:638816. https:\/\/doi.org\/10.3389\/fneur.2021.638816.","journal-title":"Front Neurol"},{"key":"732_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117098","volume":"418","author":"J Godil","year":"2020","unstructured":"Godil J, Barrett MJ, Ensrud E, Chahin N, Karam C. Refractory CIDP: clinical characteristics, antibodies and response to alternative treatment. J Neurol Sci. 2020;418:117098. https:\/\/doi.org\/10.1016\/j.jns.2020.117098.","journal-title":"J Neurol Sci"},{"issue":"1","key":"732_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010369.pub2","volume":"1","author":"AL Oaklander","year":"2017","unstructured":"Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017;1(1):cd010369. https:\/\/doi.org\/10.1002\/14651858.CD010369.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"732_CR12","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","volume":"268","author":"L Querol","year":"2021","unstructured":"Querol L, Crabtree M, Herepath M, et al. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2021;268(10):3706\u201316. https:\/\/doi.org\/10.1007\/s00415-020-09998-8.","journal-title":"J Neurol"},{"key":"732_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116497","volume":"408","author":"JA Allen","year":"2020","unstructured":"Allen JA, Gelinas DF, Freimer M, Runken MC, Wolfe GI. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? J Neurol Sci. 2020;408:116497. https:\/\/doi.org\/10.1016\/j.jns.2019.116497.","journal-title":"J Neurol Sci"},{"issue":"3","key":"732_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/jns.12344","volume":"24","author":"C Bunschoten","year":"2019","unstructured":"Bunschoten C, Blomkwist-Markens PH, Horemans A, van Doorn PA, Jacobs BC. Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2019;24(3):253\u20139. https:\/\/doi.org\/10.1111\/jns.12344.","journal-title":"J Peripher Nerv Syst"},{"key":"732_CR15","doi-asserted-by":"crossref","unstructured":"Fernandez MM, Copley-Merriman C, Arvin-Berod C, et al. Evidence gap analysis of the burden of illness and treatment of chronic inflammatory demyelinating polyneuropathy. In: ISPOR Europe, 6\u20139 November 2022, Vienna.","DOI":"10.1016\/j.jval.2022.09.164"},{"key":"732_CR16","unstructured":"US FDA (Food and Drug Administration). CDER patient-focused drug development. 2022. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/cder-patient-focused-drug-development. Accessed Jan 2024"},{"issue":"1","key":"732_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12325-020-01540-6","volume":"38","author":"JA Allen","year":"2021","unstructured":"Allen JA, Butler L, Levine T, Haudrich A. A global survey of disease burden in patients who carry a diagnosis of chronic inflammatory demyelinating polyneuropathy. Adv Ther. 2021;38(1):316\u201328. https:\/\/doi.org\/10.1007\/s12325-020-01540-6.","journal-title":"Adv Ther"},{"key":"732_CR18","unstructured":"Fernandez MM, Mordin M, Neighbors M, Tzivelekis S. A targeted literature review on the burden of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). In: Virtual German Neurological Society (DGN) Congress, 4\u20137 November 2020; Berlin"},{"issue":"12","key":"732_CR19","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1007\/s12325-023-02661-4","volume":"40","author":"M Mendoza","year":"2023","unstructured":"Mendoza M, Tran C, Bril V, Katzberg HD, Barnett-Tapia C. Symptom and treatment satisfaction in members of the US and Canadian GBS\/CIDP foundations with a diagnosis of chronic inflammatory demyelinating polyneuropathy. Adv Ther. 2023;40(12):5188\u2013203. https:\/\/doi.org\/10.1007\/s12325-023-02661-4.","journal-title":"Adv Ther"},{"key":"732_CR20","unstructured":"US FDA (Food and Drug Administration). Patient-focused drug development: collecting comprehensive and representative input. Guidance for industry, food and drug administration staff, and other stakeholders. 2020. Accessed Jan 2024. https:\/\/www.fda.gov\/media\/139088\/download"},{"issue":"3","key":"732_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"PYK Van den Bergh","year":"2010","unstructured":"Van den Bergh PYK, Hadden RDM, Bouche P, et al. European federation of neurological societies\/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2014first revision. Eur J Neurol. 2010;17(3):356\u201363. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02930.x.","journal-title":"Eur J Neurol"},{"issue":"1","key":"732_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822x05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough?: an experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382. https:\/\/doi.org\/10.1177\/1525822x05279903.","journal-title":"Field Methods"},{"issue":"7","key":"732_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839\u201342. https:\/\/doi.org\/10.1016\/j.jval.2017.11.014.","journal-title":"Value Health"},{"key":"732_CR24","volume-title":"Qualitative research and evaluation methods","author":"M Patton","year":"2002","unstructured":"Patton M. Qualitative research and evaluation methods. 3rd ed. Thousand Oaks:Sage Publications; 2002.","edition":"3"},{"issue":"8","key":"732_CR25","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMsb1710591","volume":"378","author":"L Gelinas","year":"2018","unstructured":"Gelinas L, Largent EA, Cohen IG, Kornetsky S, Bierer BE, Lynch HF. A framework for ethical payment to research participants. N Engl J Med. 2018;378(8):766\u201371. https:\/\/doi.org\/10.1056\/NEJMsb1710591.","journal-title":"N Engl J Med"},{"key":"732_CR26","unstructured":"US FDA (Food and Drug Administration). Payment and reimbursement to research subjects: guidance for institutional review boards and clinical investigators. 2018. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/payment-and-reimbursement-research-subjects. Accessed Jan 2024"},{"key":"732_CR27","unstructured":"ATLAS.ti Scientific Software Development GmbH. ATLAS.ti 22 [Qualitative data analysis software]. 2022. https:\/\/atlasti.com"},{"key":"732_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001321","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Michaud K, Nowak M, et al. Patient\u2019s experience of psoriatic arthritis: a conceptual model based on qualitative interviews. RMD Open. 2020. https:\/\/doi.org\/10.1136\/rmdopen-2020-001321.","journal-title":"RMD Open"},{"issue":"7","key":"732_CR29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/14737175.2021.1944104","volume":"21","author":"JA Allen","year":"2021","unstructured":"Allen JA, Eftimov F, Querol L. Outcome measures and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathy: from research to clinical practice. Expert Rev Neurother. 2021;21(7):805\u201316. https:\/\/doi.org\/10.1080\/14737175.2021.1944104.","journal-title":"Expert Rev Neurother"},{"key":"732_CR30","doi-asserted-by":"crossref","unstructured":"Contente M, Singh P, van Dijk BCP, Dardouri M, Bey E, Francois C. Inclusion of productivity losses in HTA evaluations in function of who bears productivity losses in the real world\u2014a qualitative assessment. In: ISPOR Europe, 2\u20136 November 2019, Copenhagen.","DOI":"10.1016\/j.jval.2019.09.2154"},{"issue":"2","key":"732_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228679","volume":"15","author":"Y Yalachkov","year":"2020","unstructured":"Yalachkov Y, Uhlmann V, Bergmann J, et al. Patients with chronic autoimmune demyelinating polyneuropathies exhibit cognitive deficits which might be associated with CSF evidence of blood-brain barrier disturbance. PLoS ONE. 2020;15(2):e0228679. https:\/\/doi.org\/10.1371\/journal.pone.0228679.","journal-title":"PLoS ONE"},{"key":"732_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1590\/0004-282X20130232","volume":"72","author":"PL dos Santos","year":"2014","unstructured":"dos Santos PL, de Almeida-Ribeiro GAN, Silva DMD, Marques Junior W, Barreira AA. Chronic inflammatory demyelinating polyneuropathy: quality of life, sociodemographic profile and physical complaints. Arq Neuropsiquiatr. 2014;72:179\u201383.","journal-title":"Arq Neuropsiquiatr"},{"key":"732_CR33","unstructured":"US FDA (Food and Drug Administration). Patient-focused drug development: methods to identify what is important to patients: guidance for industry, food and drug administration staff, and other stakeholders. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients. Accessed Janu 2024."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00732-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:58:17Z","timestamp":1747663097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00732-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00732-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Roberts, Natasha Griffiths, Kieran Thiara, Sophie Wallace, Alyson Young, and Adam Gater are employees of Adelphi Values, a health outcomes agency contracted by Sanofi to conduct the research. Nicola Williamson was an employee of Adelphi Values at the time the work was conducted and is now an employee of UCB Pharma GmbH. Omar Saeed is an employee of Sanofi, Reading, UK. Charles Minor is an employee of Sanofi, Cambridge, UK. Natalia Hawkin is an employee of Sanofi, Amsterdam, Netherlands.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All participants provided written and oral informed consent prior to the conduct of any study activities. Ethical approval and oversight were obtained from WCGIRB, an Independent Review Board in the US (IRB tracking number: 20220058). The study was performed in accordance with the Declaration of Helsinki 1964 and its later amendments and in line with guidelines related to Good Clinical Practice. All data resulting from the study were handled in accordance with US Health Insurance Portability and Accountability (HIPAA) legislation and the General Data Protection Regulation (GDPR) for the security and privacy of health data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}